Latest Conference Articles

December 13th 2021, 9:42pm

ASH Annual Meeting and Exposition

Ciltacabtagene autoleucel elicited a 97.9% objective response rate and an 82.5% stringent complete response rate in patients with relapsed/refractory multiple myeloma at a median of approximately 2 years of follow-up.

December 13th 2021, 9:05pm

ASH Annual Meeting and Exposition

Acalabrutinib, with or without obinutuzumab, induced a significant efficacy benefit for patients with treatment-naïve chronic lymphocytic leukemia compared with ibrutinib or venetoclax plus obinutuzumab, according to findings presented during the 63rd ASH Annual Meeting and Exposition.

December 13th 2021, 8:35pm

ASH Annual Meeting and Exposition

The 60mg phase 2 dose of selinexor plus pomalidomide and dexamethasone produced more durable and deep responses than the lesser selinexor dose for relapsed or refractory multiple myeloma.

December 13th 2021, 8:25pm

ASH Annual Meeting and Exposition

The combination of duvelisib plus romidepsin was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma, according to final results from the dose expansion stage of a phase 1 trial.

December 13th 2021, 8:13pm

ASH Annual Meeting and Exposition

Ibrutinib-containing combinations demonstrated continued progression-free survival benefit compared with standard bendamustine plus rituximab in elderly patients with previously untreated chronic lymphocytic leukemia.

December 13th 2021, 8:10pm

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel demonstrated favorable efficacy in elderly patients and those with other comorbidities with large B-cell lymphoma; however, adverse events were more common in some of these populations and ECOG performance status ≥2 was associated with worse outcomes and more adverse events, according to a large real-world study presented at the 2021 ASH Annual Meeting.

December 13th 2021, 7:55pm

ASH Annual Meeting and Exposition

A single infusion of ciltacabtagene autoleucel produced early and deep responses and encouraging minimal residue disease negativity in patients with multiple myeloma who experienced early clinical relapse following initial therapy.

December 13th 2021, 7:22pm

ASH Annual Meeting and Exposition

The results also demonstrated no significant difference in overall survival benefit between the treatment groups. However, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.

December 13th 2021, 7:20pm

ASH Annual Meeting and Exposition

Comparative data from the phase 1 CARTITUDE-1 trial and the real-world LocoMMotion study demonstrated that ciltacabtagene autoleucel bested standard options for patients with triple-class exposed multiple myeloma.

December 13th 2021, 7:20pm

ASH Annual Meeting and Exposition

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

December 13th 2021, 6:44pm

ASH Annual Meeting and Exposition

The first-in-class monoclonal antibody treatment for acute graft-versus-host disease had durable responses and tolerability for patients.

December 13th 2021, 6:40pm

ASH Annual Meeting and Exposition

Glofitamab, an investigational CD20xCD3 bispecific antibody, induced high response rates as monotherapy or in combination with obinutuzumab in patients with multiple relapsed or refractory follicular lymphoma.

December 13th 2021, 6:13pm

ASH Annual Meeting and Exposition

Treatment with lisocabtagene maraleucel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphomas.

December 13th 2021, 6:03pm

ASH Annual Meeting and Exposition

Cost and personal time spent on managing adverse effects for treatment with ibrutinib, acalabrutinib, or venetoclax could inform decision-making strategies for treatment selection in patients with chronic lymphocytic leukemia.

December 13th 2021, 4:25pm

ASH Annual Meeting and Exposition

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

December 13th 2021, 12:34am

ASH Annual Meeting and Exposition

The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease.

December 13th 2021, 12:30am

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

December 12th 2021, 11:19pm

ASH Annual Meeting and Exposition

Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.

December 12th 2021, 10:18pm

ASH Annual Meeting and Exposition

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

December 12th 2021, 9:46pm

ASH Annual Meeting and Exposition

Extended induction and consolidation therapy with daratumumab plus ixazomib, lenalidomide, and dexamethasone led to deepening rates of minimal residual disease for patients with standard-risk, transplant-eligible newly diagnosed multiple myeloma.